Dr Christophe Berthoux, Chief Executive of Synexus said: “We had an excellent 2012 and expect 2013 to be even better. Our forward order book, which at this time exceeds $100 million, continues to grow. In the last two years we have undergone dramatic and positive change. To meet the growth in demand we have strengthened our management team and focussed on the therapy areas where we can add most value – cardiovascular, metabolic (diabetes and obesity), bone, respiratory and CNS (dementia and pain). This new strengthened structure means that we can now look forward to the next 21 years with an industry-leading management team as well as an infrastructure which better represents our global status.”
The reorganisation includes a new global management team, reporting to the executive management board, which is responsible for HR, IT and patient recruitment. This has already resulted in great improvement in patient recruitment with over 95% of trials achieving or exceeding their targets.
Synexus has also put in place a regional structure with managing directors being responsible for the management of their regions and the day-to-day running of their sites, including their performance and profitability.
All the regions report to COO Jane Restorick. Jane has an overriding responsibility for the quality of the data produced by each clinic and for patient care and to ensure these standards and adherence to best clinical practice is the same in every Synexus clinic anywhere in the world.
Christophe explains the success of the Synexus model “We’ve seen our model being adopted far more widely as our clients in pharma and CROs get to grips with the urgent need to address productivity issues in terms of bringing new drugs to market more quickly and less expensively.”
Synexus has shown that using its own Dedicated Research Centres speeds up clinical trials, makes them more cost-effective and delivers thousands of patients. In fact it has revolutionized the way late-stage clinical trials are carried out. Traditionally, individual doctors recruited four patients or less on an opportunistic basis which, with studies involving thousands of patients, is enormously expensive and wholly impractical.
Christophe sums up “Our excellent progress is directly related to putting in place a really professional structure which delivers quality data and patients. It has been a team effort which has been actively supported by our major shareholder Lyceum Capital. We are looking forward to a sustained period of growth.”
